APA (7th ed.) Citation

WH, F., MHJ, W., EME, C., J, d. B., WH, B., LR, C., . . . EMM, S. (2025). Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS). Journal of neurology, 272(8), 530. https://doi.org/10.1007/s00415-025-13231-9

Chicago Style (17th ed.) Citation

WH, Fung, et al. "Reliability of Serum Neurofilament Light and Glial Fibrillary Acidic Protein for Detecting Disease Activity upon Discontinuation of First-line Disease-modifying Therapy in Stable Multiple Sclerosis (DOT-MS)." Journal of Neurology 272, no. 8 (2025): 530. https://doi.org/10.1007/s00415-025-13231-9.

MLA (9th ed.) Citation

WH, Fung, et al. "Reliability of Serum Neurofilament Light and Glial Fibrillary Acidic Protein for Detecting Disease Activity upon Discontinuation of First-line Disease-modifying Therapy in Stable Multiple Sclerosis (DOT-MS)." Journal of Neurology, vol. 272, no. 8, 2025, p. 530, https://doi.org/10.1007/s00415-025-13231-9.